← back to search

Aruna D. Pradhan

Bristol-Myers Squibb (Sweden) · GB
Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Diabetes, Cardiovascular Risks, and Lipoproteins, Adipokines, Inflammation, and Metabolic Diseases, Lipoproteins and Cardiovascular Health, and Peripheral Artery Disease Management.
h-index
51
citations
17,443
works
146
NIH funding
primary concept
Medicine
email

Recent publications

Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Nature Communications 2025cited by 14position: middledoi
Effectiveness of Transcarotid vs Transfemoral Carotid Stenting for Stroke Prevention
JAMA Network Open 2025cited by 12position: middledoi
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
The Lancet 2023cited by 579position: middledoi
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
New England Journal of Medicine 2022cited by 693position: firstdoi
Coronary Flow Reserve, Inflammation, and Myocardial Strain
JACC Basic to Translational Science 2022cited by 26position: middledoi
Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults
JAMA Ophthalmology 2022cited by 23position: middledoi
Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease
Circulation 2021cited by 65position: middledoi
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease
Journal of the American College of Cardiology 2020cited by 332position: lastdoi
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Cardiovascular Diabetology 2019cited by 142position: middledoi
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Journal of the American College of Cardiology 2018cited by 323position: middledoi
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
American Heart Journal 2018cited by 320position: firstdoi
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
The Lancet 2017cited by 1,300position: middledoi
Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels
Nature Communications 2016cited by 188position: middledoi
Sex Differences in the Metabolic Syndrome: Implications for Cardiovascular Health in Women
Clinical Chemistry 2013cited by 280position: firstdoi
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
The Lancet 2012cited by 805position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul M. Ridker · Gentofte Hospital6 papers (2012–2023)Peter Libby · Harvard University4 papers (2012–2022)Edward Duran · Brigham and Women's Hospital2 papers (2020–2025)Nancy R. Cook · Harvard University2 papers (2020–2025)Aaron W. Aday · American Society of Echocardiography2 papers (2020–2021)Brendan M. Everett · Harvard University2 papers (2018–2022)Jean MacFadyen · Harvard University2 papers (2012–2023)Gregory Piazza · Harvard University1 papers (2022–2022)Julie A. Lynch · University of Utah1 papers (2021–2021)JoAnn E. Manson · The University of Texas Health Science Center at Houston1 papers (2025–2025)Rob Beanlands · Ottawa Heart Institute1 papers (2022–2022)Viviany R. Taqueti · Harvard University1 papers (2022–2022)David H. Stone · White River Junction VA Medical Center1 papers (2025–2025)Dipender Gill · Nanjing Medical University1 papers (2021–2021)Scott D. Solomon · Harvard University1 papers (2022–2022)Mark A. Creager · Dartmouth–Hitchcock Medical Center1 papers (2025–2025)Robert A. deKemp · Twitter (United States)1 papers (2022–2022)Deirdre K. Tobias · Harvard University1 papers (2025–2025)Philip S. Tsao · Stanford University1 papers (2021–2021)Martin Dichgans · Martin Luther University Halle-Wittenberg1 papers (2021–2021)